DataVXAdvanced Functional MaterialsPaper
journal article·2023-07

The Synergistic Effects of Multidrug‐Loaded Nanocarriers Improve Tumor Microenvironment Responsive Chemo‐Sonodynamic Therapy of Hepatocellular Carcinoma

Xiujun Gao, Ke Bao, Yanqiu Zhang, Liyan Liu, Ying Li, Chunhong Hu, Yuqing Zhao, Wei Lu, Xi Wei

Advanced Functional Materials· Volume 33· Issue 29
Publisher page
Source abstract

Abstract

Abstract Chemotherapy works synergistically with sonodynamic therapy in a multi‐functional system and is employed to improve the therapeutic outcomes of hepatocellular carcinoma. In this study, ultrasound‐responsive multi‐functional nanoparticles (USFNPs) are loaded with dual drugs, doxorubicin, and a composite ultrasound‐sensitive agent, curcumin‐gold. The USFNPs are modified with an acid‐hydrolyzable polyethylene glycol outermost layer, making it stable in blood and normal tissues while peeling off in the acidic tumor microenvironment. The USFNPs have high specificity to liver tumor cells (Hepa 1–6 cells); can escape from lysosomes following endocytosis, and exhibit better biocompatibility. Moreover, the carriers enhance the nuclear delivery of the drugs and inhibit p‐glycoprotein (P‐gp) expression of Hepa 1–6 cells. In cancer cells, carriers convert hydrogen peroxide into oxygen, improving the hypoxic microenvironment and generating abundant superoxide anion and hydroxyl radicals. Confocal laser scanning microscopy, 1H nuclear magnetic resonance, flow cytometry, cytotoxicity, acute toxicity assays, and Western blot analysis are used to demonstrate the results. The findings suggest USFNPs as novel and potential antitumor agents for treating hepatocellular carcinoma.
Source: crossref · Quality: baseline

Research context

NanomaterialsBiomaterialsComposites

OpenAlex topics: Nanoplatforms for cancer theranostics · Ultrasound and Hyperthermia Applications · Photoacoustic and Ultrasonic Imaging

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Biomedical Engineering and Technology Tianjin Medical University Tianjin 300070 China

Department of Diagnostic and Therapeutic Ultrasonography Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center of Cancer Key Laboratory of Cancer Prevention and Therapy Tianjin Medical University Tianjin 300060 China

College of Science Civil Aviation University of China Tianjin 300300 China

The Third Surgical Department of Breast Cancer Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center of Cancer Key Laboratory of Cancer Prevention and Therapy Tianjin Medical University Tianjin 300060 China

Department of Hepatobiliary Oncology Liver Cancer Center Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center for Cancer Key Laboratory of Cancer Prevention and Therapy Tianjin's Clinical Research Center for Cancer Tianjin Medical University Tianjin 300060 China

Funding

National Natural Science Foundation of China

References (43)

Show source-provided references
1. 10.1038/s41572-020-00240-310.1038/s41572-020-00240-3 ↗
2. 10.1039/D1CS00403D10.1039/D1CS00403D ↗
3. 10.1002/anie.20191276810.1002/anie.201912768 ↗
4. 10.1002/adma.20170430710.1002/adma.201704307 ↗
5. 10.1002/adfm.20210419910.1002/adfm.202104199 ↗
6. 10.1039/C8NR08781D10.1039/C8NR08781D ↗
7. 10.1038/nrd.2018.18310.1038/nrd.2018.183 ↗
8. 10.1038/s41571-021-00539-410.1038/s41571-021-00539-4 ↗
9. 10.1002/adma.20210109510.1002/adma.202101095 ↗
10. 10.1002/adma.20200219710.1002/adma.202002197 ↗
11. 10.1002/adma.20160410510.1002/adma.201604105 ↗
12. 10.1002/adma.20190432910.1002/adma.201904329 ↗
13. 10.1002/adfm.20180014510.1002/adfm.201800145 ↗
14. 10.1002/adfm.20210038610.1002/adfm.202100386 ↗
15. 10.1038/s41571-021-00539-410.1038/s41571-021-00539-4 ↗
16. 10.1002/adfm.20200986010.1002/adfm.202009860 ↗
17. 10.1002/adfm.20210038610.1002/adfm.202100386 ↗
18. 10.1002/adfm.20190424610.1002/adfm.201904246 ↗
19. 10.1016/j.ijpharm.2022.12156710.1016/j.ijpharm.2022.121567 ↗
20. 10.1016/j.xphs.2018.10.04210.1016/j.xphs.2018.10.042 ↗
21. 10.1021/acsapm.1c0139310.1021/acsapm.1c01393 ↗
22. 10.1038/s41568-021-00382-w10.1038/s41568-021-00382-w ↗
23. 10.1002/adfm.20201073210.1002/adfm.202010732 ↗
24. 10.1002/adfm.20210216010.1002/adfm.202102160 ↗
25. 10.1016/j.addr.2018.05.00710.1016/j.addr.2018.05.007 ↗
26. 10.1002/adfm.20200986010.1002/adfm.202009860 ↗
27. 10.1021/acsnano.0c0707110.1021/acsnano.0c07071 ↗
28. 10.1002/adma.20180230910.1002/adma.201802309 ↗
29. 10.1002/adma.20180230910.1002/adma.201802309 ↗
30. 10.1021/acsami.7b1084010.1021/acsami.7b10840 ↗
31. 10.1016/j.addr.2019.05.01010.1016/j.addr.2019.05.010 ↗
32. 10.1016/j.addr.2019.05.01010.1016/j.addr.2019.05.010 ↗
33. 10.1002/adma.20180454010.1002/adma.201804540 ↗
34. 10.1021/acs.accounts.8b0019510.1021/acs.accounts.8b00195 ↗
35. 10.1002/adma.20190279110.1002/adma.201902791 ↗
36. 10.1038/s41580-021-00404-310.1038/s41580-021-00404-3 ↗
37. 10.1002/adma.20200321410.1002/adma.202003214 ↗
38. 10.1038/s41551-017-0115-810.1038/s41551-017-0115-8 ↗
39. 10.1038/nrc.2015.310.1038/nrc.2015.3 ↗
40. 10.1016/j.addr.2017.03.00410.1016/j.addr.2017.03.004 ↗
41. Wiig H. · Crit. Rev. Biomed. Eng. · 1990 · 18 · 27
42. 10.1002/jcb.2118710.1002/jcb.21187 ↗
43. Boucher Y. · Cancer Res. · 1996 · 56 · 4264